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Abstract
The role of p53 as “a guardian of the genome” has been well established in somatic cells. However, its role in pluripotent
stem cells remains much more elusive. Here, we discuss research progress in understanding the role of p53 in pluripotent
stem cells and in pluripotent stem cell-like cancer stem cells. The p53 protein, which plays a key role in embryonic stem
cells, was first discovered in 2005. Landmark studies of p53-related reprogramming elucidated this protein’s importance
in induced pluripotent stem cells in 2009. The p53-related safety concerns in pluripotent stem cells have been raised in
stem cell-based therapy although the use of iPSCs in therapeutic application is promising. Because cancer stem cells have
profiles similar to those of pluripotent stem cells, we also describe potential strategies for studies in cancer stem cells and
cancer treatments. The new discoveries of p53 family proteins in pluripotent stem cells have made possible
stable progress in stem cell transplantation efficiency and safety, as well as treatment strategies targeting
cancer stem cells based on pluripotent stem cell technology.
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Highlights
p53 is a switch in embryonic stem cells.
The p53 switch critically inhibits the generation of
induced pluripotent stem cells.
Reactivation of p53 is a potential way to treat tumors
by inhibiting formation of cancer stem cells.
Background
Evidence of desire for eternal youthfulness and regener-
ation has been used in Chinese fairy tales, such as “The
Monkey King’s Journey to the West”, for more than
500 years. Although just a fairy tale, the theme of the
story can be interpreted to mean “regeneration medicine”,
one of the hottest research topics today. The existence of
endogenous pluripotent stem cells and embryonic stem
cells (ESCs) holds great promise for regenerative medi-
cine. Induced pluripotent stem cells (iPSCs) were first
generated from mouse somatic cells in 2006 through viral
insertion of four transcription factors: Oct4, Sox2, Klf4,
and cMyc [1].
A year later, it was observed that human adult cells
were also capable of being converted into pluripotent
stem cells under similar conditions [2, 3]. Due to their
self-renewal and ability to differentiate into any cell type,
human iPSCs have the potential to replace damaged or
diseased cells, thus holding great promise for their use
in the development of stem cell-based treatments. The
ability to design patient-specific human iPSCs minimizes
the chance of transplant rejection providing the greatest
potential for their use in regenerative medicine. Key
findings of iPSC research have changed our views on cell
differentiation and provided better models with which to
study disease mechanisms, create effective systems for
drug screening, enable manufacture of useful cells for
transplantation treatments, and provide data for other
basic studies and clinical applications. Consequently, the
2012 Nobel Prize in Physiology or Medicine was
awarded to Dr. Shinya Yamanaka for the pioneering re-
search on iPSCs and to Sir John Gurdon for his funda-
mental work on reprogramming cells in frogs [4, 5].
However, despite the great potential of pluripotent
stem cell-based cell therapy, some important issues re-
garding safety concerns have been raised, especially their
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ability to induce tumorigenesis and teratoma formation
[6]. To address the issue of safety and efficiency, much
effort has focused on the development of new methods
for iPSC generation through the use of integrating and
non-integrating recombinant viruses [7–12], DNA ex-
pression vectors [13], episomal vectors [14, 15], mini-
circle vectors [16], and liposomal magnetofection [17].
Chemical-based methods [18] that result in chemically
induced pluripotent stem cells [19] appear to be the
most promising methods of reprogramming among the
non-DNA methods, which include the use of proteins
[20, 21] and mRNA molecules [22]. These advances have
significantly improved reprogramming efficiency and, at
the same time, directly or indirectly improved iPSC qual-
ity. However, these methods do not directly resolve the
safety concerns regarding iPSCs, especially tumorigenesis.
Furthermore, some studies have shown that the efficiency
improvements achieved by disabling the tumor-suppressor
p53 largely compromises safety [23].
The protein p53 has been described as “a guardian
of the genome” that protects somatic cells from
tumorigenesis. However, whether p53 plays the same
role in pluripotent stem cells is much more elusive.
While efficiency in iPSC generation has been achieved,
tumor-related safety studies involving iPSCs are lim-
ited. In fact, some iPSC generation methods may even
undermine iPSC safety with respect to tumorigenesis.
The current use of iPSCs in clinical trials is therefore
limited due to tumorigenic risks. We thus discuss the
role of p53 in pluripotent stem cells for clinical appli-
cation and in pluripotent stem cell-like cancer cells,
and how pluripotent stem cell technology can be used
for cancer treatment.
p53 is a switch in embryonic stem cells
While the tumor-suppressor p53 activation in somatic
cells during stress results in cell-cycle arrest and apoptosis,
its activities in pluripotent stem cells remain unexplored.
Different roles of p53 in ESCs, however, continue to be
discovered. At the end of 2004, p53 was found to play a
key role in the differentiation of mouse embryonic stem
cells [24], and this has been used to address some of the
safety concerns raised regarding the use of iPSCs. DNA
damage leads to high activation of p53 expression which
suppresses Nanog, a key ESC transcription factor, and in-
duces ESCs to differentiate into cell types that could effi-
ciently execute cell death to remove damaged DNA [24].
When DNA damage occurs in ESCs, phosphorylation of
p53 at serine 315 occurs leading to high expression of the
p53 protein. In particular, two sequences within the
Nanog promoter region are regulated by p53 [24]. Our ex-
tensive analysis shows that the activation of p53 inhibits
the core transcription factor Nanog, thereby promoting
stem cell differentiation in response to DNA damage in
ESCs and thus finally inhibiting tumorigenesis.
Under normal conditions, with an intact p53 signaling
pathway, ESCs can be differentiated by shifting culture
conditions from mouse ESC (mESC) medium with mouse
leukemia inhibitory factor (Lif) to mouse embryonic fibro-
blast (mEF) medium supplemented with retinoic acid
(RA) (Fig. 1a) [24]. Under normal conditions, it is impos-
sible for a differentiated cell to revert back to a stem cell
after it has crossed the intact p53 shield (Fig. 1a).
In contrast, the differentiated cells could be de-
differentiated or reprogrammed back to ESC status when
the p53 switch is turned off in humanized p53S315A
knock-in mouse ESCs (Fig. 1b). This mechanism can be
Fig. 1 p53 is a switch in embryonic stem cells. Reversible transitions between differentiated cells and embryonic stem cells (ESCs) can occur when p53
is switched off. The protein p53 separates differentiated cells from ESCs when the p53 switch is on. a Under normal conditions, with an intact p53
signaling pathway, ESCs can differentiate when culture conditions are shifted from mouse ESC (mESC) medium containing leukemia inhibitory factor
(Lif) for mouse ESCs to mouse embryonic fibroblast (mEF) medium supplemented with retinoic acid (RA). The differentiation process is depicted as cells
differentiating from the top to the bottom of the developmental hill. A differentiated cell that has crossed an intact p53 shield cannot return to the
top of this hill, which is in the pluripotent stem cell state. b Conversely, without p53 (as showed in the figure, the p53 is far from the system and the
developmental hill is compressed) differentiated cells can be easily reprogrammed to pluripotent ESCs. For example, differentiated cells
can be de-differentiated or reprogrammed to ESCs when the p53 switch is off in humanized p53S315A knock-in mouse ESCs as reported
in our previous study [24]
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used to allow cells without intact functional p53 to be re-
programmed back to ESCs (Fig. 1b), as shown in the sup-
plemental figures in [24]. These findings were consistent
with the first experimental data showing ESC-like in-
duction from mouse testis with p53 loss by Kanatsu-
Shinohara and colleagues [25]. Interestingly, although
ES-like cells could not be generated from the wild-type
germ stem cells after long-term culture, p53 gene
knockout cells could produce ES-like cells, which also
form teratomas with full pluripotent differentiation po-
tential when transplanted into mice [25].
In contrast to the findings noted above, recent studies
have revealed that p53 might be involved in negative
feedback pathways in the absence of DNA damage in
mouse ESCs. For example, Abdelalim and Tooyama
found that p53 was required for mouse ESC self-renewal
[26]. In addition, they also determined that the p53 in-
hibitor pifithrin-alpha might be responsible for the nega-
tive feedback and activation of ESC proliferation and
self-renewal [26]. These findings show the complexity of
p53 function in ESCs.
The detailed mechanism of the pluripotency switch by
p53 protein isoforms was elegantly discovered by Unge-
witter and Scrable in 2010 [27]. This study showed that
the half level expression of the deleted p53 protein ver-
sion, ¦△40p53, caused a loss of pluripotency in ESCs and
initiation of differentiation into somatic cells, while in-
creased dosage of ¦△40p53 maintained pluripotency and
inhibited differentiation. The protein activity targeted
Nanog and the IGF-1 receptor, which played a central
role in the switch between pluripotency and differenti-
ation. In addition to the p53 protein isoform function in
the switch, the other two p53 family members, p63 and
p73, which were discovered in 1997–1998 [28–31],
might also be involved in reprogramming according to
recent studies [32, 33].
These two p53 homologues have specific functional
differences from p53 and from one another. Mice lacking
p63 are born with developmental defects of the limbs and
skin caused by impaired ectodermal differentiation during
embryogenesis [32], while p73-deficient mice suffer from
neurological, pheromonal, and inflammatory defects, but
not tumors [33]. A review has discussed the functions
of p63 and p73 in the regulation of adult stem-like cells
in cooperation with p53 function in cell survival, self-
renewal and apoptosis versus senescence, although
there is limited information about their complex func-
tions in various aspects of stem cell regulation [34]. It
has been observed that p73 is highly expressed in ESCs,
suggesting it might also be involved in iPSC generation
[35]. On the other hand, p63 has been reported to play
important roles in iPSCs through its interactions in sev-
eral different pathways [36]. Considering the complex
interactions among the three family members and re-
lated upstream and downstream cell signaling path-
ways, much more attention should be attached to stem
cell safety issues.
Activation of the p53 switch critically inhibits
generation of induced pluripotent stem cells
Typically, iPSCs are generated through insertion of viral
genome into the sequences of a set of four pluripotency-
associated genes: Oct4, Sox2, cMyc, and Klf4 [1–3].
Such reprogramming has been successful in mouse and
human skin fibroblasts and several other somatic cell
types [37], as illustrated in Fig. 2. Human fibroblast cells
Fig. 2 p53 is a critical inhibitor in induced pluripotent stem cells (iPSCs). iPSC generation in normal fibroblasts with intact p53 requires the strong
effects of four transcription factors, and leaky outcomes are observed. In contrast, iPSC generation coupled with p53 loss requires only two factors
and exhibits markedly higher efficiency. a During normal development, totipotent stem cells at the top of the developmental hill gradually descend to
become somatic cells at the bottom of the hill. A model of human iPSCs is provided in the upper-left corner. A model of human fibroblast
cells is presented in the lower-left corner. Under normal conditions, with an intact p53 signaling pathway, the four transcription factors Oct4
(O), Sox2 (S), c-Myc (M), and Klf (K), which are represented by thick arrows from the top of the hill, promote the reprogramming of fibroblast
cells into iPSCs. However, p53 dramatically attenuates the effects of these factors into much weaker forces, which are depicted as thin lines. In
particular, iPSC generation across the p53 shield occurs only in certain cases at a low rate of approximately 0.01–0.1%, as reported previously
[1–3]. b A markedly higher rate of 20% [38] suggests that cell identities shift nearly freely and reversibly between iPSCs and fibroblast cells
under conditions of p53 loss. Furthermore, only Oct4 and Sox2 are sufficient for iPSC generation in this situation
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could be de-differentiated into iPSCs through the over-
expression of the four reprogramming factors (Fig. 2a).
However, iPSC generation was initially a very slow and
inefficient process, lasting approximately 2 weeks for
mouse cells and 4 weeks for human cells. Furthermore,
the original conversion of somatic cells into iPSCs oc-
curred at an extremely low rate: approximately 0.01% in
human [2, 3] and 0.1% in mouse cells [1]. This low con-
version efficiency was also reported in another pioneering
work of human iPSC generation [3]. Through overexpres-
sion of Oct4, Sox2, c-Myc, and Klf4, human fibroblast
cells were de-differentiated into pluripotent stem cells but
can dramatically be switched off by overexpressing p53.
Therefore, iPSC generation occurs only in leaky inci-
dences in which the cell manages to by-pass the p53 shield
(as indicated by the red arrow in Fig. 2a) which supports
the finding that, in the absence of p53, the process of
iPSC generation would become simple. This has been
experimentally proven in research where iPSC gener-
ation efficiency was greatly improved in fibroblasts
lacking p53, reaching 20% [38], and the parental fibro-
blast cells assumed iPSC-like status under the ESC
culture conditions (Fig. 2b).
p53 expression not only reduces iPSC generation effi-
ciency, but its deletion also replaces the reprogramming
factors. It has been reported that deletion of c-Myc from
the four-factor gene cocktail could generate iPSCs but
that the yield is dramatically low-efficient iPSCs. How-
ever, a greatly improved reprogramming efficiency (by
10%) of parental cells generated into iPSCs was seen if
p53 was switched off [38]. More research groups have
produced iPSCs by using only two factors, Oct4 and
Sox2, but under reduced levels of p53 [39]. It was dem-
onstrated that the use of small molecule cell lineage
specifiers in their “seesaw model” could be used to re-
program cells without the need for using the four tran-
scription factors [40]. Thus, these data suggest that it is
possible to generate iPSCs by turning on pluripotent
stem cell genes in a more balanced manner without the
need to use the four reprogramming factors [40, 41].
The p53 pathway switches on when DNA damage oc-
curs; hence, only cells having no DNA damage will be
able to undergo reprogramming [42, 43]. p53 is there-
fore so important for the quality control of damage-free
iPSCs that its functions should not be ignored, especially
in clinical trials [43].
Reactivation of p53 might control proliferation of
cancer stem cells with malignant pluripotency
All iPSC generation proteins (cMyc, Klf4, Nanog, Oct4,
and Sox2) are expressed either individually or collectively
in many cancer cell types [44, 45]. However, p53 inactiva-
tion or deletion significantly increases reprogramming ef-
ficiency, as observed in mice derived from iPSCs with p53
knockout [38]. These data, together with many other simi-
lar studies, strongly suggest that tumor reprogramming
and iPSC generation share similar pathways. Therefore, the
risk of tumorigenesis in iPSC-based stem cell application is
of major concern. We therefore speculate that cancer stem
cells may be generated through a reprogramming.
Accordingly, a recent study found that the production
of pluripotent stem cells, which is similar to the creation
of the so-called “carcinogenic foci,” can also be used as
an experimental model for the study of cancer develop-
ment and generation of possible treatment strategies
[46]. Similar data have also been discussed with iPSC-
based cancer stem cells and cancer modeling [47].
Some studies have linked iPSCs and pluripotent stem-
like cancer cells. Kitajima et al. observed that deleting
retinoblastoma protein (Rb) and N-ras genes in combin-
ation with oncogenic Trp53 mutations resulted in cancer
stem-like cells, showing elevated expression of embry-
onic genes, carcinogenic identities, and sensitivity to
cancer stem cell target compounds [48]. In many tumor
cells, RB and p53 are frequently inactivated. However,
deletion of Rb and p53 may result in an undifferentiated
state but not in a cancer-like status as found by Kitajima
et al. [48].
If these data are representative of tumor or cancer
stem cell initiation, then strategies based on pluripotent
stem cell technology investigating cancer stem cells
might be developed for cancer study and treatment
(Fig. 3). In Fig. 3, the green sphere represents a normal
iPSC, which is located at the top of the developmental
hill. In contrast, the red ball represents a cancer stem
cell with certain safety system defects, such as p53 loss,
RB deletion, N-RAS abnormalities, and others. The
pluripotent stem-like cancer stem cells (CSCs) may be
located in an unknown location inside the body and
may be transferable or metastasize to other locations
(Fig. 3). We therefore suggest the use of methods with
the ability to corner cancer stem cells, such as the re-
activation of p53, the activation of Rb, and the correc-
tion of the abnormal N-ras gene or other genes which
may inhibit cancer stem cells and achieve the final goal
of the treatment (Fig. 3).
Shown as a red sphere, the tumor stem cell can freely
transfer from a point in the developmental hill to some
other point, including pluripotent stem-like and metastasis-
like status. Once the normal activity of p53 is reactivated,
the pluripotent stem-like status can be restricted and the
cancer stem cell loses most of its stem cell properties. Pre-
vious findings have shown that activation of p53 by nutlin,
a small-molecule antagonist of MDM2, leads to the rapid
differentiation of human ESCs [49]. Because of the exist-
ence of several p53 mutations, other compounds, interfer-
ing RNAs, or antibodies specifically targeting the mutant
p53 pathways must be developed.
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A well-designed paper published a discovery that the
undifferentiated state was induced by Rb-p53 double
inactivation in mouse somatic cells in 2015 [50]. Using
inactivated retinoblastoma tumor suppressor protein
(Rb) together with trp53 mutant in vivo and in vitro
models, they found that Rb-p53 double inactivation re-
sulted in an undifferentiated reprogramming but without
carcinogenic conversion [48]. They built triple abnormal-
ity Rb(–/–):N-ras(–/–) MEFs with carcinogenic mutation
in Trp53, termed RN6 cells. The RN6 cells showed sphere
formation potential, very high expressions of embryonic
genes, and appeared to be carcinogenic [48]. Furthermore,
RN6 cells were sensitive to specific agents that targeted
cancer stem cells [48]. These findings suggest that the
genetic interaction between Rb and p53 determines the
undifferentiated property, and the triple gene abnormality
leads to pluripotent cancer stem cell; thus, the triple genes
worked together to make tumorigenic pluripotent cancer
stem cell. These data further suggested that these genes
might be targets for cancer stem cell-based treatments.
Pluripotent-like cancer stem cells showing that malig-
nancy can only be controlled when p53-Rb-Nras pathways
are reactivated so that the cells are forced to develop into
differentiated cells that are no longer invasive or meta-
static, as illustrated in Fig. 3.
Conclusion: the p53 switch critically impacts
pluripotent stem cell applications
The protein p53 has long been established as a key fac-
tor for the safety of adult cells. However, recent studies
of pluripotent stem cells, including ESCs and iPSCs,
have found that p53 is also a key player in pluripotent
stem cell differentiation and in reprogramming to gener-
ate induced pluripotency. Given what is currently known
Fig. 3 The reactivation of the p53 safety switch rescues cells from a malignant cancer stem cell fate. Research strategies for cancer stem cells might be
developed from pluripotent stem cell technology. Based on the recent discovery of cancer stem cells and on iPSC studies, we look forward to
the development of treatment strategies for cancer stem cells with pluripotent stem cell-like properties (pluripotent stem cell-like CSCs). The
green sphere represents normal iPSCs, which are located at the top of the developmental hill. The red sphere represents a cancer stem cell with
certain safety system defects, such as p53 loss, retinoblastoma protein (Rb) deletion, and RAS abnormalities, among others. Pluripotent stem
cell-like CSCs may be located at a certain point along the pathway down the developmental hill and may be transferable or may metastasize
to other locations. Cancer stem cells might have p53 loss or multiple gene function abnormalities that affect, for example, Rb and N-ras. We
hypothesize a method to restrict cancer stem cells with abnormal p53-Rb-Nras signaling pathway disorders. This objective could be achieved
through the reactivation of p53, the activation of Rb, and the correction of the abnormal N-ras gene or other genes via a similar process to that used
to inhibit cancer stem cells and reach final treatment goals. a Tumor stem cells can exhibit abnormal stem cell differentiation (red sphere). They can
freely transfer to other points on the developmental hill, including the location that represents pluripotent stem cell-like cells. b If the normal activity of
p53 is restored, p53 can limit cancer stem cells by inducing the loss of most stem cell properties. c Other types of cancer stem cells might require the
reactivation of two genes, such as Rb and p53, that are restricted or inhibited to cause these cells to lose their metastatic potential. d To control the
most powerful cancer stem cells, it might be necessary to reactivate all three pathways. These cells will then be forced to completely differentiate,
causing them to lose their invasiveness and their metastatic and/or proliferative potential
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regarding the generation of stem cells, p53-related activ-
ities must be carefully assessed in pluripotent stem cell-
based research and applications.
Pluripotent stem cells, including ESCs and iPSCs, are
capable of transforming into malignant teratomas, carcin-
omas, or CSCs once p53 is not controlled. In contrast, the
activation of p53 alone or in association with other factors
is capable of inhibiting cancer via inhibition of stem cell-
related mechanisms. As such, the use of p53 is a potential
therapeutic strategy in the management of cancer by
maintaining normal and genetically safe cells.
Reactivation of p53 might control and rescue cells
from switching into cancer stem cells with malignant
pluripotency. However, due to other p53 protein iso-
forms, such as the deleted p53 isoform mentioned above
[27], we should also carefully check which of the p53
isoforms regulate stem cell pluripotency in addition to
improving p53 protein stability and activity. Other p53
family members, including p63 and p73, also have op-
posite functional isoforms which can also interfere with
p53 proteins [28–36].
As discussed above, undifferentiated reprogramming
resulting from Rb-p53 double inactivation might be a
major target of the cancer stem cell treatment strategy.
The triple abnormality RN6 cells showed not only pluri-
potency but also cancer formation potential. RN6 cells
with pluripotency and tumorigenesis have already been
found to be sensitive to agents that target against cancer
stem cells. Targeting the pluripotency as a whole to deal
with cancer stem cells, similar to the cell RN6 in which
the p53 proteins might be at the center of the regulation
target, would be a good strategy. Since p53 switches off
pluripotency during differentiation plays major roles in
pluripotent stem cells and in pluripotent cancer cells,
the activated p53 switch in cancer stem cell management
should be applied to cancer treatment.
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